At Ashion®, we provide industry-leading next-generation clinical decision support approaches that leverage the genetic information from a patient’s tumor and normal genomes. Our clinical genomics testing laboratory offers unparalleled genomic data analysis and interpretation approaches to assist clinicians and patients in navigating the field of precision medicine.
The GEM ExTra® test uncovers true tumor-specific (somatic) alterations.
The GEM ExTra® test is Ashion Analytics’ flagship clinical assay. In a single test, the GEM ExTra reports clinically actionable mutations, copy number alterations, transcript variants, and fusions, detected in any gene in the patient’s DNA or RNA.
The strategy of the GEM ExTra test is to uncover true tumor-specific (somatic) alterations by comparing the sequence of the tumor against the paired normal DNA from each patient. The test also includes whole-transcriptome RNA profiling, interrogating the patient’s tumor transcriptome for fusions and transcriptional variants known to be relevant to cancer (e.g., EGFR vIII).
Each tumor’s cancer-specific alterations are then queried against a proprietary knowledge base to identify potential therapeutic associations. The final report provides the physician with a list of FDA-approved agents that are associated with tumor-specific DNA alteration(s), as well as biomarker summaries on the variant(s) found and tumor-specific evidence for drug matches, including matches with investigational agents, as available on clinicaltrials.gov.
- Sequences the coding region of the entire exome and full transcriptome
- High sensitivity for detecting point mutations, translocations, and fusions.
- Target enrichment followed by sequencing on a NovaSeq 6000 (Illumina, Inc.)
- Quick turnaround time: 14 days
- Tumor-specific variations identified with >99% accuracy when using both tumor and normal DNA
- Germline subtraction decreases false-positive rate
- Solid tumors and hematologic cancers
- FFPE, fresh frozen, bone marrow aspirates. Peripheral blood or saliva for normal samples.
RUO Exome Sequencing
Ashion utilizes NGS to selectively sequence exomes.
Exome sequencing is as an efficient strategy to selectively sequence all of the protein-coding genes within the genome. Ashion’s exome sequencing employs a similar tumor-normal approach of the GEM ExTra® and includes copy number and structural events. A technical report with run quality metrics is provided along with sequence data in the form of Variant Call Files (VCF). RUO exome sequencing is currently offered to research/academic groups and those involved in clinical trials.
- Currently offered to research/academic groups involved in clinical trials
- Can be selected independently or ordered in tandem with RNA Seq to confirm presence of therapeutically actionable target(s)
- Technical report with run quality metrics provided along with sequence data in the form of VCFs
- Solid tumors and heme cancers
- FFPE, fresh frozen, bone marrow aspirates, biopsied tumors. Peripheral blood or saliva for normal samples.
RUO RNA Sequencing
RNA Sequencing increases the likelihood of a therapeutic response.
RNA sequencing (RNA Seq) uses the capabilities of Next-Generation Sequencing (NGS) to reveal a snapshot of RNA presence and quantity from a genome at a given moment in time, providing the ability to look at alternative gene spliced transcripts, post-transcriptional changes, gene fusion, mutations such as single nucleotide polymorphisms (SNPs) and changes in gene expression. RNA Seq can
be used to identify and then prioritize identified targets based on whether or not they are expressed in the transcriptome, thus increasing the likelihood of a therapeutic response.
- Currently offered to research/academic groups and those involved in clinical trials
- Technical report with run quality metrics provided along with sequence data in the form of VCFs.
- Fresh Frozen Tissue